Is BCAB or BDRX more undervalued in 2026?

CirclFi compares BioAtla, Inc. (BCAB) and Biodexa Pharmaceuticals plc (BDRX) using 13 institutional-grade valuation models. BCAB has a Quality of Company score of 3.4/10 while BDRX scores 1.7/10.

Which is a better buy — BCAB or BDRX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do BCAB and BDRX valuations compare?

BCAB at $4.05 and BDRX at $3.36 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

BCAB vs BDRX Valuation Comparison 2026 — Intrinsic Value Analysis

BCAB

Biotechnology

BioAtla, Inc.

Quality

3.4

out of 10

Value Trap

LOW

Price

$4.05

Last close

Models

7/13

Active

BDRX

Biotechnology

Biodexa Pharmaceuticals plc

Quality

1.7

out of 10

Value Trap

—

Price

$3.36

Last close

Models

6/13

Active

Model-by-Model Comparison

Model	Type	BCAB Fair Value	BCAB Upside	BDRX Fair Value	BDRX Upside
Bayesian DCF	Intrinsic	$1.80	-55.7%	$0.89	-73.5%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.19	-95.5%	$3.04	-7.9%
Dynamic NAV	Asset-Based	$22.05	+444.4%	$16.83	+413.0%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for BCAB vs BDRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BCAB vs BDRX — Which Stock Is More Undervalued?

BCAB scores higher with a 3.4/10 quality rating vs BDRX's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing BioAtla, Inc. (BCAB) and Biodexa Pharmaceuticals plc (BDRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BCAB currently trades at $4.05 with a QOC of 3.4/10, while BDRX trades at $3.36 with a QOC of 1.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).